Inventiv Health — Q2 2016 Earnings Presentation
18 slides from Inventiv Health's earnings presentation, Aug 9, 2016
Slide 1: inVentiv Health Second Quarter 2016 Earnings Presentation
inVentiv Health Second Quarter 2016 Earnings Presentation August 12, 2016 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains forward-looking statements. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We caution readers that certain important factors may have affected and could in the future affect our actual
Slide 3: Quarterly Highlights
Quarterly Highlights Record financial performance in Q2 built on recent momentum Organic net revenue(1) growth of 17% (15% reported net revenue growth) Adjusted EBITDA(2) growth of 47% to $92mm Year-to-date organic net revenue(1) growth of 20% (17% reported net revenue growth) Signed preferred partn
Slide 4: Clinical Update
Clinical Update Continued strong performance in Q2 Organic net revenue(1) growth of 14% (11% reported net revenue growth) Adjusted EBITDA(2) growth of 50% Backlog conversion remained stable Growth was strongest in core, complex therapeutic areas Business development remained strong Net Book-to-bill
Slide 5: Commercial Update
Commercial Update Continued momentum in Q2 Organic net revenue(1) growth of 20% (18% reported net revenue growth) Adjusted EBITDA(2) growth of 31% Selling Solutions strength and Communications business drove results Significant demand and pipeline for outsourced commercial offering Deepened relation
Slide 6: Consolidated inVentiv Health Q2 2016 Financial Update
Consolidated inVentiv Health Q2 2016 Financial Update The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegment revenue which totaled approximately $4.8 million for the three months ended 6/30/2016, approximately $9.3 million for the six months e
Slide 7: Clinical Performance
Clinical Performance The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegment revenue which totaled approximately $4.8 million for the three months ended 6/30/2016, approximately $9.3 million for the six months ended 6/30/2016, approximately $3.
Slide 8: Clinical Backlog
Clinical Backlog Net Book-to-Bill = Net New Wins / Revenue Earned. (1)
Slide 9: Commercial Performance
Commercial Performance Net Revenues(1) ($ millions) Adjusted EBITDA(2) ($ millions) 18% 21% 37% 31% 16.4% 18.2% 15.6% 17.6% The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegment revenue which totaled approximately $4.8 million for the three m
Slide 10: Adjusted Free Cash Flow and Net Leverage
Adjusted Free Cash Flow and Net Leverage Adjusted Free Cash Flow(1) ($ millions) Net Leverage(2) ($ millions) Adjusted Free Cash Flow = Adjusted EBITDA – Capex +/- Changes in Net Working Capital (changes in Net Working Capital was approximately $7 million in Q2 2015 and approximately $(2) million in
Slide 11: Appendix
Appendix fe inVentiv > 11 ©2016 AllRights Reserved Health
Slide 12: Adjusted EBITDA Reconciliation
For the Quarter and Last Six Months Ended June 30, 2016 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 17 for footnotes.
Slide 13: Segment Adjusted EBITDA Reconciliation, Quarter Ended June 30, 2016
For the Quarter Ended June 30, 2016 ($ millions) Segment Adjusted EBITDA Reconciliation Note: Please refer to slide 18 for footnotes.
Slide 14: Segment Adjusted EBITDA Reconciliation, Quarter Ended June 30, 2015
Segment Adjusted EBITDA Reconciliation Note: Please refer to slide 18 for footnotes. For the Quarter Ended June 30, 2015 ($ millions)
Slide 15: Segment Adjusted EBITDA Reconciliation, Six Months Ended June 30, 2016
For the Six Months Ended June 30, 2016 ($ millions) Segment Adjusted EBITDA Reconciliation Note: Please refer to slide 18 for footnotes.
Slide 16: Segment Adjusted EBITDA Reconciliation, Six Months Ended June 30, 2015
Segment Adjusted EBITDA Reconciliation Note: Please refer to slide 18 for footnotes. For the Six Months Ended June 30, 2015 ($ millions)
Slide 17: Adjusted EBITDA Footnotes
Adjusted EBITDA Footnotes (a) Represents non-cash compensation charges. (b) Represents non-cash adjustments resulting from the revaluation of certain items such as deferred revenue and deferred rent recognized in connection with our prior acquisitions. (c) Represents the annual sponsor management fe
Slide 18: Segment Adjusted EBITDA Footnotes
Segment Adjusted EBITDA Footnotes (a) Represents the loss from continuing operations of certain subsidiaries that we have designated as unrestricted for purposes of our debt instruments. We are permitted to exclude the impact of these unrestricted subsidiaries when calculating Adjusted EBITDA in acc